Publicaciones en colaboración con investigadores/as de Universidad de Jaén (17)

2022

  1. Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines

    Neurotoxicity Research, Vol. 40, Núm. 6, pp. 1645-1652

2020

  1. Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer (Cancer Gene Therapy, (2019), 10.1038/s41417-019-0137-3)

    Cancer Gene Therapy

  2. Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents

    AAPS PharmSciTech, Vol. 21, Núm. 5

  3. Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer

    Cancer Gene Therapy, Vol. 27, Núm. 9, pp. 657-668

2019

  1. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

    Cancer Biology and Medicine, Vol. 16, Núm. 4, pp. 688-699

2018

  1. DNA methylation patterns as molecular biomarkers: An overview in colorectal cancer

    European Journal of Anatomy, Vol. 22, Núm. 4, pp. 303-316

2017

  1. Gastrointestinal stromal tumours: An actualized overview

    European Journal of Anatomy, Vol. 21, Núm. 2, pp. 97-112

  2. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study

    European Journal of Pharmaceutical Sciences, Vol. 102, pp. 24-34

  3. Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines

    Nano Research, Vol. 10, Núm. 3, pp. 856-875

  4. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Last advances in nanocarriers-based drug delivery systems for colorectal cancer

    Current Drug Delivery, Vol. 13, Núm. 6, pp. 830-838

2015

  1. Specific colon cancer cell cytotoxicity induced by bacteriophage E gene expression under transcriptional control of carcinoembryonic antigen promoter

    International Journal of Molecular Sciences, Vol. 16, Núm. 6, pp. 12601-12615

  2. Temozolomide resistance in glioblastoma cell lines: Implication of MGMT, MMR, P-glycoprotein and CD133 expression

    PLoS ONE, Vol. 10, Núm. 10

2014

  1. Application of nanotechnology in the treatment and diagnosis of gastrointestinal cancers: Review of recent patents

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Núm. 1, pp. 21-34

  2. CO-17 Estudio de MGMT, MMR y P-gp como posibles meca-nismos de resistencia a la temozolamida en líneas tumoralesde glioblastoma

    I Congreso Nacional Multidisciplinar de Jóvenes Investigadores: libro de Actas : Facultad de Ciencias, Universidad de Granada 19, 20 y 21 de febrero de 2014 (Asociación de Investigadores Extranjeros (AINVEX)), pp. 55-59

2013

  1. Colon cancer therapy: Recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 13, Núm. 8, pp. 1204-1216

2012

  1. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

    Journal of Translational Medicine, Vol. 10, Núm. 1